Read More
FDA approves pembrolizumab plus axitinib for advanced RCC
(HealthDay)—The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the U.S. Food and Drug Administration announced Friday.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
Read More
Subscribe to:
Post Comments (Atom)
0 Response to "FDA approves pembrolizumab plus axitinib for advanced RCC"
Post a Comment